TY - JOUR T1 - Changes in English medication safety indicators throughout the COVID-19 pandemic: a federated analysis of 57 million patients’ primary care records in situ using OpenSAFELY JF - medRxiv DO - 10.1101/2022.05.05.22273234 SP - 2022.05.05.22273234 AU - Louis Fisher AU - Lisa E. M. Hopcroft AU - Sarah Rodgers AU - James Barrett AU - Kerry Oliver AU - Anthony J. Avery AU - Dai Evans AU - Helen Curtis AU - Richard Croker AU - Orla Macdonald AU - Jessica Morley AU - Amir Mehrkar AU - Seb Bacon AU - Simon Davy AU - Iain Dillingham AU - David Evans AU - George Hickman AU - Peter Inglesby AU - Caroline E. Morton AU - Becky Smith AU - Tom Ward AU - William Hulme AU - Amelia Green AU - Jon Massey AU - Alex J. Walker AU - Chris Bates AU - Jonathan Cockburn AU - John Parry AU - Frank Hester AU - Sam Harper AU - Shaun O’Hanlon AU - Alex Eavis AU - Richard Jarvis AU - Dima Avramov AU - Paul Griffiths AU - Aaron Fowles AU - Nasreen Parkes AU - Ben Goldacre AU - Brian MacKenna Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/05/07/2022.05.05.22273234.abstract N2 - Objective To describe the impact of the COVID-19 pandemic on safe prescribing, using the PINCER prescribing indicators; to implement complex prescribing indicators at national scale using GP data.Design Population based cohort study, with the approval of NHS England using the OpenSAFELY platform.Setting Electronic health record data from 56.8 million NHS patients’ general practice records.Participants All NHS patients registered at a GP practice using TPP or EMIS computer systems and recorded as at risk of at least one potentially hazardous PINCER indicator between September 2019 and September 2021.Main outcome measure Monthly trends and between-practice variation for compliance with 13 PINCER measures between September 2019 and September 2021.Results The indicators were successfully implemented across GP data in OpenSAFELY. Hazardous prescribing remained largely unchanged during the COVID-19 pandemic, with only small reductions in achievement of the PINCER indicators. There were transient delays in blood test monitoring for some medications, particularly ACE inhibitors. All indicators exhibited substantial recovery by September 2021. We identified 1,813,058 patients at risk of at least one hazardous prescribing event.Conclusion Good performance was maintained during the COVID-19 pandemic across a diverse range of widely evaluated measures of safe prescribing.WHAT IS ALREADY KNOWN ON THIS TOPICWHAT IS ALREADY KNOWN ON THIS TOPICPrimary care services were substantially disrupted by the COVID-19 pandemic.Disruption to safe prescribing during the pandemic has not previously been evaluated.PINCER is a nationally adopted programme of activities that aims to identify and correct hazardous prescribing in GP practices, by conducting manual audit on subgroups of practices.WHAT THIS STUDY ADDSWHAT THIS STUDY ADDSFor the first time, we were able to successfully generate data on PINCER indicators for almost the whole population of England, in a single analysis.Our study is the most comprehensive assessment of medication safety during the COVID-19 pandemic in England, covering 95% of the population using well-validated measures.Good performance was maintained across many PINCER indicators throughout the pandemic.Delays in delivering some medication-related blood test monitoring were evident though considerable recovery was made by the end of the study period.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare the following: B.G. has received research funding from the Laura and John Arnold Foundation, the NHS National Institute for Health Research (NIHR), the NIHR School of Primary Care Research, the NIHR Oxford Biomedical Research Centre, the Mohn-Westlake Foundation, NIHR Applied Research Collaboration Oxford and Thames Valley, the Wellcome Trust, the Good Thinking Foundation, Health Data Research UK, the Health Foundation, the World Health Organisation, UKRI, Asthma UK, the British Lung Foundation, and the Longitudinal Health and Wellbeing strand of the National Core Studies programme; he also receives personal income from speaking and writing for lay audiences on the misuse of science.Funding StatementThis work was jointly funded by UKRI, NIHR and Asthma UK-BLF [COV0076; MR/V015737/] and the Longitudinal Health and Wellbeing strand of the National Core Studies programme. The OpenSAFELY data science platform is funded by the Wellcome Trust. B.G.'s work on better use of data in healthcare more broadly is currently funded in part by: the Wellcome Trust, NIHR Oxford Biomedical Research Centre, NIHR Applied Research Collaboration Oxford and Thames Valley, the Mohn-Westlake Foundation; all DataLab staff are supported by B.G.'s grants on this work. B.M.K. is also employed by NHS England working on medicines policy and clinical lead for primary care medicines data. The views expressed are those of the authors and not necessarily those of the NIHR, NHS England, Public Health England or the Department of Health and Social Care. The underlying research, and the development and rollout out of the PINCER intervention was funded by the Department of Health Patient Safety Research Portfolio (original PINCER trial); the Health Foundation and Academic Health Science Network East Midlands (rollout across the East Midlands as part of the Health Foundation Scaling Up Improvement Programme), and NHS England, the national Academic Health Science Network and the Health Foundation (national rollout of PINCER). A.J.A.'s current work on the evaluation of the PINCER intervention is funded by NIHR Programme Grants for Applied Research (RP-PG-1214-20012). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Health Research Authority (REC reference 20/LO/0651) and by the LSHTM Ethics Board (reference 21863).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll analytical code used in this study is openly available for inspection and re-use at https://github.com/opensafely/pincer-measures. All codelists used are openly available at OpenSAFELY Codelists (https://www.opencodelists.org/codelist/pincer/). Results are available as an online report https://reports.opensafely.org/reports/changes-in-pincer-measures-throughout-the-covid-19-pandemic/. https://github.com/opensafely/pincer-measures https://www.opencodelists.org/codelist/pincer/ https://reports.opensafely.org/reports/changes-in-pincer-measures-throughout-the-covid-19-pandemic/ ER -